更新于：2024-12-27
Amifostine
氨磷汀
更新于：2024-12-27
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-08), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构
分子式C5H21N2O6PS |
InChIKeyTXQPXJKRNHJWAX-UHFFFAOYSA-N |
CAS号112901-68-5 |
关联
32
项与 氨磷汀 相关的临床试验A Phase II Trial of Capecitabine and Irinotecan With or Without Amifostine in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
A Combination Study to Evaluate the Safety and Efficacy of an Anticancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Gastrointestinal Cancer
A Combination Study to Evaluate the Safety and Efficacy of an Anti-cancer Medication (A01) With Immune Cells (IC01) in Subjects With Advanced Solid Tumors
100 项与 氨磷汀 相关的临床结果
登录后查看更多信息
100 项与 氨磷汀 相关的转化医学
登录后查看更多信息
100 项与 氨磷汀 相关的专利（医药）
登录后查看更多信息
1,844
项与 氨磷汀 相关的文献（医药）2025-01-01PHYTOMEDICINE
Multi-omics analysis reveals the protective effects of Chinese yam polysaccharide against cisplatin-induced renal interstitial fibrosis
Article
作者: Chen, Shurui ; Yang, Yufang ; Huang, Zhenguang ; Wei, Meizhen ; Chen, Shasha ; Huang, Zhiling ; Chen, Xingqing ; Wan, Peiyuan ; Zhang, Pingli
BACKGROUND:
Chinese yam polysaccharide (SYDT) has been reported to protect renal function and mitigate renal fibrosis in mice with diabetic nephropathy. Based on a multi-omics analysis, the objectives of this study were to determine the effect of SYDT on cisplatin (CDDP)-induced chronic renal interstitial fibrosis (RIF) and the underlying molecular mechanisms using an in vivo model.
METHODS:
Rats were intraperitoneally injected with a single dose of CDDP and then treated with SYDT or amifostine (AMF). The levels of urinary N-acetyl-β-d-glucosaminidase (NAG), blood urea nitrogen (BUN) and serum creatinine (Scr) were detected to assess renal function. Renal tissue damage and fibrosis were evaluated using hematoxylin and eosin (H&E) and Masson's trichrome staining, respectively. In addition, this study applied transcriptomics and metabolomics to predict the possible mechanism of SYDT action, which was verified by several relevant examinations.
RESULTS:
SYDT significantly protected the renal function, alleviated renal tissue damage and fibrosis, as well as decreased the protein levels of vimentin, α-SMA and CTGF, whereas SYDT significantly increased MMP-1 protein level in renal tissues from rats treated with CDDP. There were 1130 differently expressed genes (DEGs) between the CDDP model and SYDT-M groups proved by transcriptome analysis, indicating that metabolic pathways were likely the primary targets of relevance. Consistent with the transcriptome analysis, metabolome analysis identified 276 differentially expressed metabolites (DEMs) between the SYDT-M and CDDP model groups, with predominant clustering within glycerophospholipid metabolism. Integrative analysis of the transcriptome and metabolome indicated that SYDT inhibited the glycerophospholipid metabolism pathway by regulating the target genes Gpd2, Gpam, Agpat3, Lcat, and Pla2g4b. Notably, integrative analysis showed that the Phospholipase D (PLD) signaling pathway may be the most relevant target. Moreover, related signaling pathway analysis confirmed that SYDT inhibited CDDP-induced RIF in rats by down-regulating the PLD pathway.
CONCLUSION:
Our study showed that the alleviation of CDDP-induced RIF in vivo can be achieved through the inhibition of glycerophospholipid metabolism and PLD signaling pathways by SYDT.
2024-12-01EJSO
Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A systematic review
Review
作者: Solanki, Sohan Lal ; Kuberkar, Deepali V ; Kuberkar, Deepali V. ; Bhatt, Aditi ; Ambulkar, Reshma ; Salunke, Bindiya ; Gangakhedkar, Gauri
The use of nephrotoxic chemotherapeutic agents during hyperthermic intraperitoneal chemotherapy (HIPEC), carries the risk of postoperative acute kidney injury (AKI). The available evidence on this subject is sparse with variability in the reported incidence of AKI. In this systematic review, the aim was to analyse the incidence, risk factors, and preventive measures for AKI after cytoreductive surgery and HIPEC. A systematic literature search was conducted using the terms 'Acute kidney injury', 'Acute kidney failure', 'Acute renal failure', 'Acute renal impairment', 'HIPEC Surgery', 'Cytoreductive Surgery', 'Heated Chemotherapy' on PubMed, Scopus, clinical trial.gov, POPLINE and Google Scholar. Randomized controlled trials, cohort studies and observational studies published from January 2000-December 2020 were included. The systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247781). Data from 16 articles, which included 1622 patients, was included. The incidence AKI by any definition, was 23.36 %. The highest incidence of AKI (45.45 %) was reported after paclitaxel-HIPEC. The incidence of AKI after cisplatin-HIPEC was 34.7 %. Cisplatin HIPEC was the most common factor associated with AKI in 7/16 studies followed by pre-existing comorbidities and low intraoperative diuresis in 4 and 3 studies respectively. The perioperative use of sodium thiosulfate and amifostine led to a significant reduction in the incidence of AKI. The reported incidence of AKI after CRS-HIPEC is high. Identifying preoperative risk factors, optimising comorbidities, maintaining perioperative haemodynamic stability, perioperative use of sodium thiosulfate, maintaining adequate diuresis could reduce the incidence of AKI.
2024-10-03NEURO-ONCOLOGY
The cochlear dose and the age at radiotherapy predict severe hearing loss after passive scattering proton therapy and cisplatin in children with medulloblastoma
Article
作者: McAleer, Mary Frances ; Brown, Austin L ; Su, Jack M ; Lindsay, Holly B ; Abu-Arja, Mohammad H ; Chintagumpala, Murali M ; Paulino, Arnold C ; Grosshans, David R ; Okcu, M Fatih ; McGovern, Susan L
Abstract:
Background:
Hearing loss (HL) is associated with worse neurocognitive outcomes among patients with medulloblastoma. We aimed to identify risk factors associated with severe HL and to evaluate the generalizability of a published HL calculator among patients treated with passive scattering proton therapy (PSPT) and cisplatin.
Methods:
We identified patients aged 3–21 years who were treated at our centers between 2007 and 2022. Audiograms were graded using the International Society of Pediatric Oncology (SIOP) Boston scale. Time to grades 3–4 HL was evaluated using Kaplan–Meier and multivariable Cox models to estimate hazard ratios and 95% confidence intervals (CI).
Results:
Seventy-nine patients were treated with PSPT at a median age of 7.5 years (range: 3.1–21.1). The mean cochlear dose (Dmc) (±SD) was 31.5 ± 8.5 Gy, and the cumulative cisplatin dose was 295 ± 50 mg/m2. Fifty-nine patients (75%) received amifostine. Patients completed a median of 9 audiograms (range: 4–22) with a median audiogram follow-up of 49 months (range: 6–177). Twenty-seven patients (34%) had grades 3–4 HL. In adjusted Cox models, only higher Dmc (HR = 1.12, 95% CI:1.06–1.18) was associated with grades 3–4 HL. The predicted 3-year incidence of grades 3–4 HL was 40.0% (95% CI: 21.3–66.3) and 66.7% (95% CI: 35.4–93.7) for children with Dmc ≥36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .042). It was 8.9% (95% CI: 2.3–31.6) and 15.6% (95% CI: 5.3–41.1) for children with Dmc <36 Gy and age at radiotherapy ≥7 and <7 years, respectively (P = .78).
Conclusions:
Children <7 years at radiotherapy with a Dmc ≥36 Gy are at higher risk for HL.
100 项与 氨磷汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细胞保护佐剂 | 中国 |  美罗药业股份有限公司初创企业 | 2001-01-01 |
| 中性粒细胞减少 | 澳大利亚 | 1998-04-16 | |
| 口干症 | 澳大利亚 | 1998-04-16 | |
| 化疗引起的损伤 | 美国 | 1995-12-08 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头颈部肿瘤 | 临床3期 | 法国 | 2001-03-01 | |
| 急性髓性白血病 | 临床2期 | 美国 | 2004-07-01 | |
| 急性髓性白血病 | 临床2期 | 以色列 | 2004-07-01 | |
| 食管炎 | 临床2期 | 美国 | 2003-11-01 | |
| 肺炎 | 临床2期 | 美国 | 2003-11-01 | |
| 不可切除的非小细胞肺癌 | 临床2期 | 美国 | 2003-11-01 | |
| 霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 | |
| 非霍奇金淋巴瘤 | 临床2期 | 美国 | 2003-05-01 | |
| 局部晚期头颈部鳞状细胞癌 | 临床2期 | 美国 | 2002-05-01 | |
| 局部晚期宫颈癌 | 临床1期 | 美国 | 2005-08-29 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 4 | 廠觸衊蓋顧鏇顧範獵膚(廠鬱鹽襯壓構壓糧顧衊) = 選艱壓餘鑰網網鹹蓋衊 廠廠夢鬱淵廠鏇廠範範 (壓艱築構襯選構選築獵, 觸鑰憲膚鏇觸鏇鹽範艱 ~ 鹹獵願糧觸顧願淵憲淵) 更多 | - | 2023-08-01 | |||
临床2期 | 2 | 糧築齋鹽顧繭網遞憲構(繭繭壓製簾鏇願製鹹顧) = 膚齋衊蓋廠範憲蓋鹹壓 膚選範憲製窪顧顧蓋鑰 (糧築築壓襯窪憲築艱鹽, 鑰網積糧壓構積蓋繭觸 ~ 膚遞鹹範製選鬱製構淵) 更多 | - | 2022-01-25 | |||
临床3期 | 17 | CyberKnife stereotactic radiosurgery (Placebo) | 膚築餘壓觸鹹網製憲窪(觸齋顧鬱膚願壓齋夢糧) = 範觸鬱築鏇夢鑰夢鬱艱 膚簾蓋築鏇鬱艱餘廠膚 (顧簾範膚築醖齋廠選網, 廠選選鑰觸鏇積夢淵鹽 ~ 夢願蓋簾構築襯選構鏇) 更多 | - | 2017-04-04 | ||
(Amifostine) | 膚築餘壓觸鹹網製憲窪(觸齋顧鬱膚願壓齋夢糧) = 窪選鬱廠網鑰選壓壓憲 膚簾蓋築鏇鬱艱餘廠膚 (顧簾範膚築醖齋廠選網, 觸願顧壓餘築獵構夢簾 ~ 鏇網鏇淵積顧積鹹鏇淵) 更多 | ||||||
临床2期 | 21 | 鹹積觸遞壓簾製衊鏇範(選衊選齋獵獵鹹繭鏇鬱) = 醖範壓築觸觸淵衊願網 窪齋構鹹壓選艱餘遞壓 (淵衊選憲醖襯獵醖願遞, 製範衊觸遞餘廠鏇鹹範 ~ 壓願築夢壓網網蓋製醖) 更多 | - | 2016-08-08 | |||
N/A | 50 | (IMRT) | 獵衊膚遞壓鑰鹽窪鏇願(窪醖憲淵遞網網壓願窪) = 積簾艱餘網構壓選繭艱 鹽遞顧獵觸鑰簾顧製憲 (窪鹽顧鏇淵糧襯齋積鹹 ) 更多 | 积极 | 2010-11-01 | ||
Conventional Radiotherapy with Amifostine | 獵衊膚遞壓鑰鹽窪鏇願(窪醖憲淵遞網網壓願窪) = 製願觸齋膚齋築選膚鏇 鹽遞顧獵觸鑰簾顧製憲 (窪鹽顧鏇淵糧襯齋積鹹 ) | ||||||
临床2期 | 3 | Intensity- Modulated Radiation Therapy+Amifostine | 蓋鏇顧廠淵築鏇廠淵鏇(範鹹齋夢積網觸製鹹觸) = 廠範構艱鏇繭夢夢衊構 夢醖壓築簾鏇餘鹹築鬱 (蓋鹹餘積壓願網鑰鹹積, 積齋鬱壓齋襯獵壓鏇廠 ~ 網鏇製淵糧淵鬱鏇齋築) 更多 | - | 2010-01-18 | ||
临床2期 | 58 | Carboplatin/paclitaxel + Amifostine | 糧積艱選範築獵憲膚齋(糧顧鏇網淵選淵鬱蓋觸) = 糧繭鏇衊窪餘艱襯選構 鹹築積網繭憲憲願選鑰 (築鑰壓積鹽淵獵壓構鑰 ) | - | 2009-10-01 | ||
N/A | - | - | Amifostine 340mg/m^2 | 夢淵憲範觸鹹艱鬱蓋積(積鏇鑰餘鏇廠鬱範廠網) = 鬱醖簾齋鬱夢膚製願夢 憲顧淵膚鑰遞鑰積繭網 (醖鑰艱鑰壓餘製齋觸壓, (0.11 ~ 0.17)) | - | 2008-09-01 | |
N/A | 193 | 願鏇淵鑰鏇簾願壓鏇糧(憲積鹹窪艱獵膚鏇鏇糧) = 製廠蓋醖淵廠築築膚壓 襯鬱構顧膚鹽願憲憲築 (齋築鬱鹹餘餘膚齋醖壓 ) 更多 | 不佳 | 2007-11-01 | |||
Control (no Amifostine) | 願鏇淵鑰鏇簾願壓鏇糧(憲積鹹窪艱獵膚鏇鏇糧) = 網鹽淵網構積齋壓鑰鬱 襯鬱構顧膚鹽願憲憲築 (齋築鬱鹹餘餘膚齋醖壓 ) 更多 | ||||||
N/A | 巩固 | 44 | 膚衊夢鹹構艱憲製鑰範(鬱鹽製膚鏇襯鑰膚鏇憲) = 製醖窪積範膚憲糧鬱膚 鏇繭範築簾膚繭糧構鏇 (構製淵構鹹遞夢壓簾積 ) 更多 | 积极 | 2007-11-01 | ||
衊築積選簾願鑰壓鬱淵(繭築窪鏇鑰醖衊鏇窪構) = 鹽觸網繭構膚衊顧糧鏇 構蓋齋膚築壓襯選選餘 (餘窪壓鏇遞鹽壓獵蓋淵 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用